ABSTRACT
The aim of this paper is to discuss and update criteria that can guide the diagnosis, prognosis and treatment of canine and feline mammary neoplasms. It was elaborated during the IV Mammary Pathology Meeting: Diagnosis, Prognosis and Treatment of the Canine and Feline Mammary Neoplasia, held on April 29th and 30th, 2019 in Belo Horizonte MG, Brazil, sponsored by the Laboratory of Comparative Pathology of the Federal University of Minas Gerais (UFMG), with the support of the Brazilian Association of Veterinary Pathology (ABPV) and Brazilian Association of Veterinary Oncology (ABROVET). Academics from several regions of Brazil were present and contributed to this work.(AU)
Subject(s)
Animals , Cats , Dogs , Dogs , Cats , Mammary Neoplasms, Animal/diagnosis , Therapeutics/veterinaryABSTRACT
The aim of this paper is to discuss and update criteria that can guide the diagnosis, prognosis and treatment of canine and feline mammary neoplasms. It was elaborated during the IV Mammary Pathology Meeting: Diagnosis, Prognosis and Treatment of the Canine and Feline Mammary Neoplasia, held on April 29th and 30th, 2019 in Belo Horizonte MG, Brazil, sponsored by the Laboratory of Comparative Pathology of the Federal University of Minas Gerais (UFMG), with the support of the Brazilian Association of Veterinary Pathology (ABPV) and Brazilian Association of Veterinary Oncology (ABROVET). Academics from several regions of Brazil were present and contributed to this work.
Subject(s)
Animals , Cats , Dogs , Dogs , Cats , Mammary Neoplasms, Animal/diagnosis , Therapeutics/veterinaryABSTRACT
The purpose of this paper is to establish criteria that could guide the diagnosis, prognosis and treatment of caninemammary neoplasias. It was elaborated during the Mammary Pathology Meeting: Diagnosis, Prognosis and Treatment ofthe Canine Mammary Neoplasia, held on November 6th and 7th, 2010 in Belo Horizonte MG, Brazil. Academics fromseveral regions of Brazil were present and contributed to this work. After three years, a new discussion was foundnecessary in order to address important questions: 1 - Have Brazilian DVMs applied the consensus? 2 - What were the maindifficulties in applying the consensus? 3 - What were the obtained results? 4 - What were the main differences among thevarious oncology services/groups? 5 - How could the criteria be improved and uniformed? A spreadsheet that allowed datacollection and an abstract was submitted by each oncology service/group from various parts of the country. Based on theabstracts we identified the main differences in diagnosis and therapeutic conducts among the groups. These differences haveguided the discussions of the II Mammary Pathology Meeting and the publication of a second consensus that has beenrevised and updated. The II Mammary Pathology Meeting: Diagnosis, Prognosis and Treatment of the Canine mamaryNeoplasia, was held on December 9th, 10thand 11th, 2013 in Belo Horizonte MG, sponsored by the Laboratory ofComparative Pathology of the Federal University of Minas Gerais (UFMG), with the support of the Brazilian Associationof Veterinary Pathology (ABPV) and Brazilian Association of Veterinary Oncology (ABROVET). Academics from severalregions of Brazil were present and contributed to this work.(AU)
Subject(s)
Animals , Female , Dogs , Mammary Neoplasms, Animal/diagnosis , Mammary Neoplasms, Animal/therapy , Antineoplastic Protocols , BrazilABSTRACT
The purpose of this paper is to establish criteria that could guide the diagnosis, prognosis and treatment of caninemammary neoplasias. It was elaborated during the Mammary Pathology Meeting: Diagnosis, Prognosis and Treatment ofthe Canine Mammary Neoplasia, held on November 6th and 7th, 2010 in Belo Horizonte MG, Brazil. Academics fromseveral regions of Brazil were present and contributed to this work. After three years, a new discussion was foundnecessary in order to address important questions: 1 - Have Brazilian DVMs applied the consensus? 2 - What were the maindifficulties in applying the consensus? 3 - What were the obtained results? 4 - What were the main differences among thevarious oncology services/groups? 5 - How could the criteria be improved and uniformed? A spreadsheet that allowed datacollection and an abstract was submitted by each oncology service/group from various parts of the country. Based on theabstracts we identified the main differences in diagnosis and therapeutic conducts among the groups. These differences haveguided the discussions of the II Mammary Pathology Meeting and the publication of a second consensus that has beenrevised and updated. The II Mammary Pathology Meeting: Diagnosis, Prognosis and Treatment of the Canine mamaryNeoplasia, was held on December 9th, 10thand 11th, 2013 in Belo Horizonte MG, sponsored by the Laboratory ofComparative Pathology of the Federal University of Minas Gerais (UFMG), with the support of the Brazilian Associationof Veterinary Pathology (ABPV) and Brazilian Association of Veterinary Oncology (ABROVET). Academics from severalregions of Brazil were present and contributed to this work.
Subject(s)
Female , Animals , Dogs , Mammary Neoplasms, Animal/diagnosis , Mammary Neoplasms, Animal/therapy , Antineoplastic Protocols , BrazilABSTRACT
As neoplasias mamárias são as mais frequentes em cadelas, representando 25 a 30 por cento do total das afecções neoplásicas das fêmeas caninas. Durante a carcinogênese ocorrem várias modificações na expressão de proteínas, como a Cyr61, envolvida na proliferação celular e na angiogênese. Assim, este estudo teve por objetivo determinar o perfil de expressão dessa proteína, por meio da técnica de imunoistoquímica, em glândulas mamárias normais e neoplásicas de cadelas. Para tal, foram selecionados 10 casos de cada um dos diagnósticos: adenoma simples, carcinoma complexo e carcinoma simples sólido, além de 10 fragmentos de glândulas mamárias normais, perfazendo o total de 40 fragmentos. O anticorpo policlonal anti-Cyr61 apresentou marcação em células epiteliais mamárias normais, evidenciando seu papel nos mecanismos de apoptose e proliferação celular. Houve ainda acentuada imunomarcação em tecidos mamários normais e com adenomas, e marcação discreta em carcinomas, diferente do padrão de expressão observado no tecido mamário de mulheres. A expressão constitutiva da proteína Cyr61 foi demonstrada no tecido mamário canino, constituindo uma alternativa de investigação neoplásica para as alterações mamárias de cadelas.
Mammary glands are the most usual sites of tumors in bitches, representing 25 to 30 percent of all types of cancer. During cancer genesis, several genetic changes alter the expression of different proteins like Cyr61, a peptide involved in cell proliferation and angiogenesis. This work aimed to determine through immunohistochemistry the expression profile of Cyr61 in normal and neoplastic mammary glands from bitches. So, 10 cases of each diagnose were selected: simple adenoma, complex carcinoma, simple solid carcinoma and fragments of normal mammary glands, in a total of 40 cases. Sections were subjected to immunohistochemistry, employing primary antibodies directed Cyr61. Cyr61 labeling of normal mammary epithelial cells is probably linked to its role in apoptosis and cellular proliferation. The labeling was more intense in normal and adenoma fragments and was discrete in the labeling malignant tumor sections, a different feature of expression from previously reports in human breast cancer. Immunohistochemical analysis with polyclonal antibody Cyr61 demonstrated the constitutive expression of the protein and contributed to neoplastic research alternative for tumors in bitches.
ABSTRACT
Mammary glands are the most usual sites of tumors in bitches, representing 25 to 30% of all types of cancer. During cancer genesis, several genetic changes alter the expression of different proteins like Cyr61, a peptide involved in cell proliferation and angiogenesis. This work aimed to determine through immunohistochemistry the expression profile of Cyr61 in normal and neoplastic mammary glands from bitches. So, 10 cases of each diagnose were selected: simple adenoma, complex carcinoma, simple solid carcinoma and fragments of normal mammary glands, in a total of 40 cases. Sections were subjected to immunohistochemistry, employing primary antibodies directed Cyr61. Cyr61 labeling of normal mammary epithelial cells is probably linked to its role in apoptosis and cellular proliferation. The labeling was more intense in normal and adenoma fragments and was discrete in the labeling malignant tumor sections, a different feature of expression from previously reports in human breast cancer. Immunohistochemical analysis with polyclonal antibody Cyr61 demonstrated the constitutive expression of the protein and contributed to neoplastic research alternative for tumors in bitches.
As neoplasias mamárias são as mais frequentes em cadelas, representando 25 a 30% do total das afecções neoplásicas das fêmeas caninas. Durante a carcinogênese ocorrem várias modificações na expressão de proteínas, como a Cyr61, envolvida na proliferação celular e na angiogênese. Assim, este estudo teve por objetivo determinar o perfil de expressão dessa proteína, por meio da técnica de imunoistoquímica, em glândulas mamárias normais e neoplásicas de cadelas. Para tal, foram selecionados 10 casos de cada um dos diagnósticos: adenoma simples, carcinoma complexo e carcinoma simples sólido, além de 10 fragmentos de glândulas mamárias normais, perfazendo o total de 40 fragmentos. O anticorpo policlonal anti-Cyr61 apresentou marcação em células epiteliais mamárias normais, evidenciando seu papel nos mecanismos de apoptose e proliferação celular. Houve ainda acentuada imunomarcação em tecidos mamários normais e com adenomas, e marcação discreta em carcinomas, diferente do padrão de expressão observado no tecido mamário de mulheres. A expressão constitutiva da proteína Cyr61 foi demonstrada no tecido mamário canino, constituindo uma alternativa de investigação neoplásica para as alterações mamárias de cadelas.
ABSTRACT
Mammary glands are the most usual sites of tumors in bitches, representing 25 to 30% of all types of cancer. During cancer genesis, several genetic changes alter the expression of different proteins like Cyr61, a peptide involved in cell proliferation and angiogenesis. This work aimed to determine through immunohistochemistry the expression profile of Cyr61 in normal and neoplastic mammary glands from bitches. So, 10 cases of each diagnose were selected: simple adenoma, complex carcinoma, simple solid carcinoma and fragments of normal mammary glands, in a total of 40 cases. Sections were subjected to immunohistochemistry, employing primary antibodies directed Cyr61. Cyr61 labeling of normal mammary epithelial cells is probably linked to its role in apoptosis and cellular proliferation. The labeling was more intense in normal and adenoma fragments and was discrete in the labeling malignant tumor sections, a different feature of expression from previously reports in human breast cancer. Immunohistochemical analysis with polyclonal antibody Cyr61 demonstrated the constitutive expression of the protein and contributed to neoplastic research alternative for tumors in bitches.
As neoplasias mamárias são as mais frequentes em cadelas, representando 25 a 30% do total das afecções neoplásicas das fêmeas caninas. Durante a carcinogênese ocorrem várias modificações na expressão de proteínas, como a Cyr61, envolvida na proliferação celular e na angiogênese. Assim, este estudo teve por objetivo determinar o perfil de expressão dessa proteína, por meio da técnica de imunoistoquímica, em glândulas mamárias normais e neoplásicas de cadelas. Para tal, foram selecionados 10 casos de cada um dos diagnósticos: adenoma simples, carcinoma complexo e carcinoma simples sólido, além de 10 fragmentos de glândulas mamárias normais, perfazendo o total de 40 fragmentos. O anticorpo policlonal anti-Cyr61 apresentou marcação em células epiteliais mamárias normais, evidenciando seu papel nos mecanismos de apoptose e proliferação celular. Houve ainda acentuada imunomarcação em tecidos mamários normais e com adenomas, e marcação discreta em carcinomas, diferente do padrão de expressão observado no tecido mamário de mulheres. A expressão constitutiva da proteína Cyr61 foi demonstrada no tecido mamário canino, constituindo uma alternativa de investigação neoplásica para as alterações mamárias de cadelas.
ABSTRACT
Um estudo de coorte histórico foi desenvolvido incluindo 116 pacientes com câncer de mamaatendidas no Hospital Femina, Grupo Hospitalar Conceição (GHC), Ministério da Saúde (MS),entre setembro de 1997 e dezembro de 2000. Foi aplicado o índice prognóstico de Nottingham(IPN) na população em estudo e avaliada a sua associação com a recidiva da doença. O IPNconseguiu identificar um grupo com bom prognóstico, em que de 26 pacientes somente 2 (7,7%)evoluíram para recidiva, e um grupo de 32 pacientes com pobre prognóstico, em que 24 delas(75%) evoluíram para recidiva em cinco anos. Nesta amostra composta de pacientes provenientesda rede pública, a média e o desvio-padrão do tamanho tumoral foi de 3,1 ± 1,8 cm e somente25% das mulheres apresentaram tumores menores do que 2 cm na primeira consulta no hospitalterciário. Isso sugere que o diagnóstico de câncer de mama ainda está sendo realizado tardiamente,em nosso meio.
A history cohort study that included 116 breast cancer patients treated at the Femina Hospital, GrupoHospitalar Conceição (GHC), Health Ministry (HM), between September 1997 to December 2000 wasconducted. The Nottingham Prognostic Index (NPI) and its association with the disease recidivationwas assessed in the study population. The NPI identified two groups; good prognosis group (n = 26) with7.7% recidivation and a poor prognosis group (n = 32) with 75% recidivation at 5 years. The tumorsize in our study population was 3.1 ± 1.8 cm and it was less than 2 cm in only 25% of the patients atthe first consultation at a tertiary hospital. These observations suggested that the breast cancer diagnosis isperformed late in our environment.